Signos

/01 — THE SCENEThe arm. The sensor. The buzz.

It is 7:42 a.m. in a kitchen somewhere in Denver. A woman pours oat milk into her coffee, takes a sip, and her phone buzzes. Not a text. Not a notification. A nudge - polite, almost embarrassed - from a small disc on her upper arm. The disc has been quietly sampling the fluid under her skin every five minutes. Her glucose, it reports, is climbing faster than usual. The app suggests a ten-minute walk before her 8 a.m. call.

This is what Signos has built: a feedback loop short enough to actually change a behavior. Not a quarterly bloodwork report. Not a calorie ledger that lies by Tuesday. A sensor, a model, a nudge, in roughly the time it takes to butter a piece of toast.

Fig. 1 — A continuous glucose monitor: the only roommate that watches your breakfast without judgment.

/02 — THE PROBLEMOne in three, and counting.

Roughly one in three American adults is metabolically unhealthy, a phrase that does a lot of work. It means insulin resistance brewing in the background. It means weight gain that feels like a moral failure but is mostly a chemistry one. It means a public health story that has, for forty years, been told mostly in food pyramids and willpower lectures.

The standard playbook - count calories, eat less, move more - has not been catastrophically wrong. It has just been catastrophically generic. The same banana spikes one person and barely budges another. The same evening run smooths glucose for some and frays it for others. The signal is personal. The advice, until recently, was not.

Into that gap walked GLP-1 drugs - Ozempic, Wegovy, Mounjaro - which work, expensively and not without side effects. Signos's argument is not that these drugs are bad. It is that the same Americans who can't afford a $1,000-a-month injection can probably afford a $50 sensor and a smarter app. And many of them might prefer it.

/03 — THE FOUNDERS' BETFour people, one hypothesis.

Sharam Fouladgar-Mercer is not, by background, a doctor. He is a serial entrepreneur whose previous company, AirPR, was sold to Onclusive. He started Signos in 2018 with Bill Tancer (a data-behavior wonk whose book Click sold like, well, hot data), William Dixon (a physician and digital health builder) and Pierre Wehbe (an engineer with a soft spot for hard signals).

Their bet was simple and very Silicon Valley in the worst possible way - until it worked. Take a piece of medical hardware that had been refined for diabetics over two decades. Aim it at a much larger market: people who don't yet have diabetes but are quietly headed there. Wrap it in software that does the math humans cannot. Sell it directly, monthly, with the friction of a streaming subscription.

Fig. 2 — Founders not pictured, because the founders prefer the product to be pictured.

/04 — THE PRODUCTWhat the box contains.

A Signos kit arrives in a small box that does not look medical. Inside: a Dexcom Stelo biosensor, a sticky disc with a hair-thin filament that goes on the back of the upper arm. The app does the rest. It reads glucose data every fifteen minutes over Bluetooth, layers in your meals, your steps, your sleep from Apple Health or Google Health Connect, your weight from a smart scale if you have one, and your stress signals from a wearable.

What it doesn't do is treat you like a diabetic. It doesn't issue red alarms. It doesn't beep at 54 mg/dL the way medical CGMs do. It is calibrated for people who are mostly fine and want to stay that way - which is, it turns out, a much larger group than people who already aren't.

Fig. 3 — Seven years, three rounds, one regulatory first. The Y axis is patience.

/05 — THE PROOFThe data, with feeling.

Anecdotes are easy. Signos's bet is that the data is the story. Internal research and published case studies show users surfacing food-glucose pairings they would never have guessed - the granola that spikes worse than the cookie, the late dinner that wrecks the morning, the ten-minute walk that flattens the curve as well as skipping dessert. None of this is moralistic. It is just true, in a way that calorie counts never quite manage to be.

Fig. 4 — Bars sized for scale; numbers sourced from company filings, press, and the kind of public estimates that should be read with a grain of salt.

/06 — THE MISSIONOptimize metabolic health for all.

Sharam talks about Signos's mission with a phrase the marketing team has clearly never been allowed to soften: optimize metabolic health for all. The all is the load-bearing word. It is also the hardest part. Most digital health companies, in practice, optimize metabolic health for the affluent, the type-A, the already-curious. Signos is trying to make the system cheap enough, friendly enough and FDA-cleared enough to reach the people the wellness industry has historically priced out.

That ambition is why the August 2025 FDA clearance matters more than it sounds. Calling it the first OTC CGM cleared for weight management is the kind of sentence regulators love and headlines mostly skip. Translated: Signos can now be sold without a prescription, without a doctor's gatekeeping, to the millions of Americans who would never have walked into an endocrinologist's office in the first place.

/07 — WHY IT MATTERSThe next decade of glucose.

Continuous glucose monitors are about to become the Fitbits of the 2020s - except, unlike step counts, they actually correlate with outcomes that insurance companies care about. Dexcom, the hardware company quietly behind half this industry, knows it. So does Abbott. So do the half-dozen consumer apps trying to layer software on the same sensor.

Signos has, for the moment, two things its competitors do not. The first is the only FDA OTC clearance for weight management specifically. The second is a head start on the messy, deeply personal layer that turns a stream of glucose readings into something resembling advice. The first can be copied. The second compounds.

Back to the kitchen in Denver.

It is now 7:51 a.m. The woman has taken the walk. Her glucose, by the time she sits down to her 8 a.m. call, is back where the app wanted it. She is two pounds lighter than last month and, more usefully, less anxious about the difference between oatmeal and a bagel. None of this is dramatic. None of it would make a billboard. It is, instead, the kind of small, durable behavior change that the diet industry has been promising and failing to deliver for half a century.

Signos's bet is that this is what health technology should feel like - quiet, specific, occasionally inconvenient, and finally, finally personal.

/08 — THE FILEWhere to find Signos.